Autopsy report · NCT04064346
Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
Cause of deathFunding or business
“The decision is based on a thorough reassessment of the commercial potential of lixivaptan as a potential best-in-class therapy for patients with autosomal dominant polycystic kidney disease (ADPKD).”
Life of this trial
- Registered 2 years 2 months before it started.
- Ran for about 9 months before it stopped.
- 12 participants enrolled.
- Results were posted on the registry 6 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Palladio Biosciences
- Sponsor type
- Industry
- Conditions
- Autosomal Dominant Polycystic Kidney; ADPKD
- Interventions
- Lixivaptan; Placebo
- Participants
- 12
- Sites
- 43
- Countries
- Australia, Bulgaria, Hungary, Poland, Spain, Turkey (Türkiye), United Kingdom, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.